Celyad doses first AML patient at final dose level in CYAD-01 THINK trial and treats first patient with second cycle of therapy

Celyad doses first AML patient at final dose level in CYAD-01 THINK trial and treats first patient with second cycle of therapy

Celyad announces closing of global offering

Celyad announces closing of global offering

Celyad announces pricing of $47.3 million global offering

Celyad announces pricing of $47.3 million global offering

Celyad announces launch of proposed global offering

Celyad announces launch of proposed global offering

Discover our news

Upcoming events

Oct 19-23, 2018

ESMO 2018

Oct 29-30, 2018

BMWS

Nov 7-11, 2018

SITC annual meeting

Discover all events

Press material

Dear Journalists,
Please find here all information background and material for your articles.
For any media request, please refer to the contacts below.
Join our press list
Press kit

Press kit

2.4 Mo

a

Press contacts

Celyad

Nicolas Van Hoecke Director, Investor Relations & Communications

+32 (0)10 39 41 84

LifeSci Advisors

Matt Middleman

NewCap (France)

Nicolas Merigeau, Pierre Laurent

+ 33(0)1 44 71 94 94

Comfi (Belgium)

Gunther De Backer, Sabine Leclercq

+32(0) 2 290 90 91